Abstract
The ɛ4 allele of apolipoprotein E (apoE) is a risk factor for Alzheimer’s disease (AD) and cerebral amyloid angiopathy (CAA). The mechanism underlying this increased risk is not completely clear, yet mounting evidence supports the idea that the ability of apoE to interact with the amyloid-β (Aβ) peptide and influence its conformation and clearance plays a major role. Evidence to support this concept comes from in vitro and in vivo studies of apoE/Aβ interactions and the effects of these interactions on Aβ conformation and cellular clearance. Recent studies on the effect of murine and human apoE in APP transgenic mice provide direct evidence that apoE is critically involved in the in vivo converstion of Aβ into forms which contain high β-sheet content and associated cellular toxicity (neuritic plaques and CAA). These studies also suggest a role for human apoE in Aβ clearance in vivo.
Similar content being viewed by others
References
Aleshkov S., Abraham C. R., and Zannis V. I. (1997) Interaction of nascent apoE2, apoE3, and apoE4 isoforms expressed in mammalian cells with amyloid peptide β(1–40). Relevance to Alzheimer’s disease. Biochemistry 36, 10,571–10,580.
Arendt T., Schindler C., Bruckner M. K., Eschrich K., Bigl V., Zedlick D., and Marcova L. (1997) Plastic neuronal remodeling is impaired in patients with Alzheimer’s disease carrying apolipoprotein epsilon 4 allele. J. Neurosci. 17, 516–529.
Bales K. R., Verina T., Cummins D. J., Du Y., Dodel J. C., Saura J., et al. (1999) Apolipoprotein E is essential for amyloid deposition in the APPV717F transgenic mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 96, 15,233–15,238.
Bales K. R., Verina T., Dodel R. C., Du Yansheng, Altstiel L., Bender M., et al. (1997) Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nature Genet. 17, 263–264.
Beffert U., Aumont N., Dea D., Lussier-Cacan S., Davignon J., and Poirier J. (1999) Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. Mol. Brain Res. 68, 181–185.
Biere A. L., Ostaszewski B., Zhao H., Gillespie S., Younkin S. G., and Selkoe D. J. (1995) Co-expression of beta-amyloid precursor protein (betaAPP) and apolipoprotein E in cell culture: analysis of betaAPP processing. Neurobiol. Dis. 2, 177–187.
Borghini I., Barja F., Pometta D., and James R. W. (1995) Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochem. Biophys. Acta 1255, 192–200.
Boyles J. K., Pitas R. E., Wilson E., Mahley R. W., and Taylor J. M. (1985) Apolipoprotein E associated with astrocytic glia of the central nervous system and with non-myelinating glia of the peripheral nervous system. J. Clin. Invest. 76, 1501–1513.
Buttini M., Akeefe H., Lin C., Mahley R. W., Pitas R. E., Wyss-Coray T., and Mucke L. (2000) Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease. Neuroscience 97, 207–210.
Buttini M., Orth M., Bellosta S., Akeefe H., Pitas R. E., Wyss-Coray T., Mucke L., and Mahley R. W. (1999) Expression of human apolipoprotein E3 or E4 in the brains of apoe/mice: isoform-specific effects on neurodegeneration. J. Neurosci. 19, 4867–4880.
Castano E. M., Prelli F., Wisniewski T., Golabek A., Kumar R. A., Soto C., and Frangione B. (1995) Fibrillogenesis in Alzheimer’s disease of amyloid beta peptides and apolipoprotein E. Biochem. J. 306, 599–604.
Christie R. H., Chung H., Rebeck G. W., Strickland D., and Hyman B. T. (1996) Expression of the very low-density lipoprotein receptor (VLDL-r), an apolipoprotein-E receptor, in the central nervous system and in Alzheimer’s disease. J. Neuropath. Exp. Neurol. 55, 491–498.
Corder E. H., Saunders A. M., Risch N. J., Strittmatter W. J., Schmechel D. E., Gaskell P. C., et al. (1994) Protective effect of apolipoprotein E type 2 allele decreases risk of late onset Alzhimer disease. Nature Genet. 7, 180–184.
Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921–923.
Evans K. C., Berger E. P., Cho C-G., Weisgraber K. H., and Lansbury P. T. (1994) Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 92, 763–767.
Fagan A. M., Holtzman D. M., Munson G., Mathur T., Schneider D., Chang L. K., et al. (1999) Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-) and human apoE transgenic mice. J. Biol. Chem. 274, 30,001–30,007.
Fagan A. M., Younkin L. H., Morris J. C., Cole T. G., Younkin S. G. and Holtzman D. M. (2000) Differences in Aβ40/42 ratio associated with CSF lipoproteins as a function of apoE genotype. Ann. Neurol. 48, 201–210.
Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717Fβ-amyloid precursor protein. Nature 373, 523–527.
Ghersi-Egea J.-F., Gorevic P. D., Ghiso J., Frangione B., Patlak C. S., and Fensternacher J. D. (1996) Fate of cerebrospinal fluid-borne amyloid [beta]-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J. Neurochem. 67, 880–883.
Golabek A. A., Soto C., Vogel T., and Wisniewski T. (1996) The interaction between apolipoprotein E and Alzheimer’s amyloid β-peptide is dependent on β-peptide conformation. J. Biol. Chem. 271, 10,602–10,606.
Greenberg S. M., Briggs M. E., Hyman B. T., Kokoris G. J., Takis C., Kanter D. S., et al. (1996) Apolipoprotein E Σ4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke 27, 1333–1337.
Greenberg S. M., Rebeck G. W., Vonsattel J. P. G., Gomez-Isla T., and Hyman B. T. (1995) Apolipoprotein E Σ4 and cerebral hemorrhage associated with amyloid angiopathy. Ann. Neurol. 38, 254–259.
Greenberg S. M., Vonsattel J.-P. G., Segal A. Z., Chiu R. I., Clatworthy A. E., Liao A., et al. (1998) Association of apolipoprotein E Σ2 and vasculopathy in cerebral amyloid angiopathy. Neurology 50, 961–965.
Hardy J., Crook R., Perry R., Raghavan R., and Roberts G. (1994) ApoE genotype and Down’s syndrome. Lancet 343, 979–980.
Holtzman D. M., Bales K. R., Tenkova T., Fagan A. M., Parsadanian M., Sartorius L. J., et al. (2000a) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 97, 2892–2897.
Holtzman D. M., Bales K. R., Wu S., Bhat P., Parsadanian M., Fagan A. M., et al. (1999) In vivo expression of apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimers disease. J. Clin. Invest. 103, R15-R21.
Holtzman D. M., Fagan A. M., Mackey B., Tenkova T., Sartorius L., Paul S. M., et al. (2000b) ApoE facilitates neuritic and cerebrovascular plaque formation in the APPsw mouse model of Alzheimer’s disease. Ann. Neurol. 47, 739–747.
Holtzman D. M., Pitas R. E., Kilbridge J., Nathan B., Mahley R. W., Bu G., and Schwartz A. L. (1995) LRP mediates apolipoprotein E-dependent neurite outgrowth in a CNS-derived neuronal cell line. Proc. Natl. Acad. Sci. USA 92, 9480–9484.
Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Youkin S., et al. (1996) Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99–102.
Hyman B. T., West M. L., Rebeck G. W., Buldyrev S. V., Mantegna R. N., Ukleja M., et al. (1995) Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21. Proc. Natl. Acad. Sci. USA 92, 3586–3590.
Jacobsen L., Madsen P., Moestrup S. K., Lund A. H., Tommerup N., Nykjaer A., et al. (1996) Molecular characterization of a novel human hybrid-type receptor that binds the α2-macroglobulin receptor-associated protein. J. Biol. Chem. 271, 31,379–31,383.
Jellinger K. (1977) Cerebrovascular amyloidosis with cerebral hemorrhage. J. Neurol. 214, 195–206.
Ji Y., Permanne B., Sigurdsson E. M., Holtzman D. M., and Wisniewski T. (2001) Amyloid β40/42 clearance across the blood-brain barrier following intraventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. J. Alzheimer’s Dis. 3, 23–30.
Kim D. H., Iijima H., Goto K., Sakai J., Ishii H., Kim H. J., et al. (1996) Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J. Biol. Chem. 271, 8373–8380.
Kindy M. S. and Rader D. J. (1998) Reduction in amyloid A formation in apolipoprotein-E-deficient mice. Am. J. Pathol. 152, 1387–1395.
Koudinov A., Matsubara E., Frangione B., and Ghiso J. (1994) The soluble form of Alzheimer’s amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem. Biophys. Res. Comm. 205, 1164–1171.
Koudinov A. R., Koudinova N. V., Kumar A., Beavis R. C., and Ghiso J. (1996) Biochemical characterization of Alzheimer’s soluble beta protein in human cerebrospinal fluid-association with high density lipoprotein. Biochem. Biophys. Res. Comm. 223, 592–597.
Kowal R. C., Herz J., Goldstein J. L., Esser V., and Brown M. S. (1989) Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc. Natl. Acad. Sci. USA 86, 5810–5814.
LaDu M. J., Falduto M. T., Manelli A. M., Reardon C. A., Getz G. S., and Frail D. E. (1994) Isoform-specific binding of apolipoprotein E to β-amyloid. J. Biol. Chem. 269, 23,404–23,406.
LaDu M. J., Gilligan S. M., Lukens S. R., Cabana V. G., Reardon C. A., Van Eldik L. J., and Holtzman D. M. (1998) Nascent astroctye particles differ from lipoproteins in CSF. J. Neurochem. 70, 2070–2081.
LaDu M. J., Pederson T. M., Frail D. E., Reardon C. A., Getz G. S., and Falduto M. T. (1995) Purification of apolipoprotein E attenuates isoform-specific binding to β-amyloid. J. Biol. Chem. 270, 9030–9042.
Lai F., Kammann E., Rebeck G. W., Anderson A., Chen Y., and Nixon R. A. (1999) APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome. Neurology 53, 331–336.
Lansbury P. T. Jr. (1997) Structural neurology: are seeds at the root of neuronal degeneration? Neuron 19, 1151–1154.
Linton M.F., Gish R., Hubl S. T., Butler E., Esquivel C., Bry W. I., Boyles J. K., et al. (1991) Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J. Clin. Invest. 88, 270–281.
Ma J., Yee A., Brewer H. B., Das S., and Potter H. (1994) Amyloid-associated proteins alpha-1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372, 92–94.
Mahley R. W. (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622–630.
Matsubara E., Ghiso J., Frangione B., Amari M., Tomidokoro Y., Ikeda Y., et al. (1999) Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer’s disease and Down’s syndrome. Ann. Neurol. 45, 537–541.
Mayeux R., Stern Y., Ottman R., Tatemichi T. K., Tang M.-X., Maestre G., et al. (1993) The apolipoprotein Σ4 allele in patients with Alzheimer’s disease. Ann. Neurol. 34, 752–754.
Namba Y., Tomonaga M., Kawasaki H., Otomo E., and Ikeda K. (1991) Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s diesase kuru plaque amyloid in Creutzfeldt-Jacob disease. Brain Res. 541, 163–166.
Naslund J., Thyberg J., Tjernberg L. O., Wernstedt C., Karlstrom A. R., Bogdanovic N., et al. (1995) Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer’s disease brain. Neuron 15, 219–228.
Nathan B. P., Bellosta S., Sanan D. A., Weisgraber K. H., Mahley R. W., and Pitas R. E. (1994) Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264, 850–852.
Neumann M. A. (1960) Combined amyloid vascular changes and argyrophilic plaques in the central nervous system. J. Neuropathol. Exp. Neurol. 19, 370–382.
Nicoll J. A. R., Burnett C., Love S., Graham D. I., Dewar D., Ironside J. W., et al. (1997) High frequency of apolipoprotein E Σ2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann. Neurol. 41, 716–721.
Permanne B., Perez C., Soto C., Frangione B., and Wisniewski T. (1997) Detection of apolipoprotein E/dimeric soluble amyloid β complexes in Alzheimer’s disease brain supernatants. Biochem. Biophys. Res. Commun. 240, 715–720.
Pitas R. E., Boyles J. K., Lee S. H., Foss D., and Mahley R. W. (1987a) Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta 917, 148–161.
Pitas R. E., Boyles J. K., Lee S. H., Hui D., and Weisgraber K. H. (1987b) Lipoproteins and their receptors in the central nervous system. J. Biol. Chem. 262, 14,352–14,360.
Plump A. S. and Breslow J. L. (1995) Apolipoprotein E and the apolipoprotein E-deficient mouse. Annu. Rev. Nutr. 15, 495–518.
Poirer J. (1994) Apolipoprotein E in animal models of CNS injury and Alzheimer’s disease. Trends Neurol. Sci. 17, 525–530.
Premkuman D. R. D., Cohen D. L., Hedera P., Friedland R. P., and Kalaria R. N. (1996) Apolipoprotein E-Σ4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer’s disease. Am. J. Pathol. 148, 2083–2095.
Price J. L. and Morris J. C. (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann. Neurol. 45, 358–368.
Raber J., Wong D., Yu G.-Q., Buttini M., Mahley R. W., Pitas R. E., and Mucke L. (2000) Alzheimer’s disease: Apolipoprotein E and cognitive performance. Nature 404, 352–354.
Rebeck G. W., Alonzo N. C., Berezovska O., Harr S. D., Knowles R. B., Growdon J. H., et al. (1998) Structure and functions of human cerebrospinal fluid lipoproteins from individuals of different APOE genotypes. Exp. Neurol. 149, 175–182.
Rebeck G. W., Reiter J. S., Strickland D. K., and Hyman B. T. (1993) Apolipoprotein E in sporadic Alzheimer’s disease: allelic variation and receptor interactions. Neuron 11, 575–580.
Rumble B, Retalack R, Hilbich C, Simms G, Multhaup G, Martins R, et al. (1989) Amyloid A4 protein and its precursors in Down’s syndrome and Alzheimer’s disease. N. Engl. J. Med. 320, 1446–1452.
Russo C., Angelini G., Dapino D., Piccini A., Piombo G., Schettini G., et al. (1998) Opposite roles of apolipoprotein E in normal brains and in Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 95, 15,598–15,602.
Sanan D. A., Weisgraber K. H., Russel S. J., Mahley R. W., Huang D., Saunders A., et al. (1994) Apolipoprotein E associates with β amyloid peptide of Alzheimer’s disease to form novel monofibrils. J. Clin. Invest. 94, 860–869.
Schmechel D. E., Saunders A. M., Strittmattter W. J., Crain B. J., Hulette C. M., Joo S. H., et al. (1993) Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 9649–9653.
Selkoe D. J. (1997) Alzheimer’s disease: genotypes, phenotype, and treatments. Science 275, 630–631.
Shibata M., Yamada S., Kumar S. R., Calero M., Bading J., Frangione B., et al. (2000) Clearance of Alzheimer’s amyloid-β1–40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106, 1489–1499.
Soto S., Golabek A., Wisniewski T., and Castano E. M. (1996) Alzheimer’s β-amyloid peptide is conformationally modified by apolipoprotein E in vitro. Neuroreport 7, 721–725.
Stone D. J., Rozovsky I., Morgan T. E., Anderson C. P., Hajian H., and Finch C. E. (1997) Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp. Neurol. 143, 313–318.
Strittmatter W. J. and Roses A. D. (1996) Apolipoprotein E and Alzheimer’s disease. Annu. Rev. Neurosci. 19, 53–77.
Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S., and Roses A. D. (1993a) Apolipoprotein E: high avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 1977–1981.
Strittmatter W. J., Weisgraber K. H., Huang D. Y., Dong L.-Y., Salvesen G. S., Pericak-Vance M., et al. (1993b) Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform specific-effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 8098–8102.
Sullivan P. M., Mezdour H., Aratani Y., Knouff C., Najib J., Reddick R. L., et al. (1997) Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J. Biol. Chem. 272, 17,972–17,980.
Swanson L. W., Simmons D. M., Hofmann S. L., Goldstein J. L., and Brown M. S. (1988) Localization of mRNA for low density lipoprotein receptor and a cholesterol synthetic enzyme in rabbit nervous system by in situ hybridization. Proc. Natl. Acad. Sci. USA 85, 9821–9825.
Tokuda T., Calero M., Matsubara E., Vidal R., Kumar A., Permanne B., et al. (2000) Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer’s amyloid beta peptides. Biochem. J. 348, 359–365.
Vinters H. V. (1987) Cerebral amyloid angiopathy: a critical review. Stroke 18, 311–324.
Wisniewski K. E., Wisniewski H. M., and Wen G. Y. (1985) Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome. Ann. Neurol. 17, 278–282.
Wisniewski T. and Frangione B. (1992) Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 135, 235–238.
Wisniewski T., Lalowski M., Golabek A. A., Vogel T., and Frangione B. (1995) Is Alzheimer’s disease an apolipoprotein E amyloidosis? Lancet 345, 956–958.
Wood S. J., Chan W., and Wetzel R. (1996) Seeding of Aβ fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry 35, 12,623–12,628.
Yamazaki H., Bujo H., Kusunoki J., Seimiya K., Kanaki T., Morisaki N., et al. (1996) Elements of neural adhesion molecules and a yeast vacuolar protein sorting receptor are present in a novel mammalian low density lipoprotein receptor family member. J. Biol. Chem. 271, 24,761–24,768.
Yang D. S., Small D. H., Seydel U., Smith J. D., Hallmayer J., Gandy S. E., and Martins R. N. (1999) Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner. Neuroscience 90, 1217–1226.
Yang D.-S., Smith J. D., Zhou Z., Gandy S., and Martins R. N. (1997) Characterization of the binding of amyloid-β peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J. Neurochem. 68, 721–725.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Holtzman, D.M. Role of apoE/Aβ interactions in the pathogenesis of Alzheimer’s disease and cerebral amyloid angiopathy. J Mol Neurosci 17, 147–155 (2001). https://doi.org/10.1385/JMN:17:2:147
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/JMN:17:2:147